Feng Tao is a Chinese Principal Consultant in Korea Health Industry Development Institute (KHIDI), which is a government-affiliated institute. He has made meaningful contribution to the entry of Korean pharmaceutical companies into Chinese markets. He’s specialty area is bio pharmaceuticals, biosimilar, chemical pharmaceuticals, IVD, cell therapy, gene therapy and genetic recombination pharmaceutical. Based on his distinctive working experiences and expertise in the healthcare industry, he has expanded
his business field including marketing, business development, Research and
Development and license in & out, etc. He has worked in Novartis in China
Oncology as a Marketing Director for 3 years, in Xian Janssen as a SFE Senior
Manager & Director for 4 years, in BMS as a Region Manager for 7 years and
Roche as a District Manager for 4 years.

Frances (Fran) M. Zipp, President & CEO of Lachman Consultant Services, Inc.
Fran Zipp is President & CEO of Lachman Consultant Services, Inc. As an expert in compliance enhancement, she develops program solutions to meet GXP compliance requirements and delivers strategic guidance and direction toward implementation of effective solutions to client needs. Ms. Zipp has extensive experience in the pharmaceutical, biologic and biotechnology industries from R&D through post-market approval. She assists and counsels Senior-level management in areas of Corporate Governance, Corporate Integrity Agreement Compliance, Consent Decree Negotiations and Resolutions, Application Integrity Policy resolution, and Due Diligence evaluations (facilities; products; technologies).

Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is
the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton’s research group is currently focused on the development of continuous
processing technology to facilitate the discovery, development and
commercialization of drug products. Prior to joining the faculty at Virginia
Commonwealth University, Dr. Gupton served as the Executive Director of North
American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University.

A biochemical engineer by training (Bordeaux Polytechnic Institute), Frédérique also holds a Master of Business Administration from KEDGE Business School. Frédérique has been working in the pharmaceutical industry for more than 20 years: first at AstraZeneca UK, working on analytical development of therapeutic proteins and antibodies, then at CDMO Bertin Pharma (now Eurofins), working mainly on generic product development and licensing out.Frédérique joined Capsugel® in 2010 as Pharmaceutical Business Development Manager, providing technical and regulatory support for new capsule-based product developments. 
Frédérique has developed specific expertise around capsule-based DPI product development and filing, supporting multiple companies in the EMEA and United States by working on innovative products.

Gary started his career in life sciences working on the ground-breaking cloning project “Dolly the Sheep”. Since then, he has held senior executive positions in a number of international biopharmaceutical, CRO and MedTech companies.He joined SGS in 2014 as business manager for the biologics characterization and R&D sites across Europe, then in 2016 was appointed as Global Head of Regulatory and Compliance for the life science segment.
Now Global Head for Life Sciences at SGS since 2018, Gary now leads the business development strategy and growth plan for the integrated network of analytical testing laboratories across North America, Europe and Asia-Pacific.

Joined Bachem in 2015 when American Peptide Company was acquired by Bachem. Worked in peptide API CMO industry for more than 25 years in the areas of sales, marketing, business development, product management, and general management. Member of the board at American peptide company from 2009 to 2015. Current member of the board in Bachem Japan K.K.

Experienced Managing Editor with a demonstrated history of working in the publishing industry.  Responsible for running the day-to-day operations of TKS Publisher journals. Oversees and supervises all editorial activities of the journals such as the peer review process, article acceptance or rejection, preparing papers for publication, and producing the journal.
Second-in-command, reports directly to the editor-in-chief / managing director. Skilled in Editorial Management, Biological and Chemical Skills, Media Relations, Organization of Scientific Conferences & Webinars, and Journalism. Strong media and communication professional with a Master of Science (M.S.) focused in Agro Food Biotechnology from Università degli Studi di Milano.

Gil Roth is the President of the Pharma &
Biopharma Outsourcing Association, the trade association that advocates for
the legislative, regulatory and general business interests of CMO/CDMOs. He
previously served as the Founding Editor of Contract Pharma magazine from
1999-2014.

Dr. Gunnveig Grødeland obtained her Ph.D. in immunology and vaccinology in 2013 from the University of Oslo in Norway. She has since worked at the University of Oslo and Oslo University Hospital, interrupted by a Fulbright Scholarship to The Scripps Research Institute in San Diego. Grødeland is leading her research group on Influenza and Adaptive Immunity, and is also Dep. Director of K.G. Jebsen Centre for Influenza Vaccine Research. Her research interests has focused on development of novel vaccine formats against infectious diseases, and she has brought novel vaccine formats from construction to clinical evaluations.

Hanneke is the only lawyer-pharmacist with a PhD in the Netherlands. Therefore, she is a lawyer with an extraordinary, atypical background. Hanneke specialises in the EU and national regulatory life sciences law. She holds a PhD in pharmacokinetics and pharmacodynamics. Previously, she was an inspector for Clinical Trials and Pharmacovigilance with the Inspectorate for Healthcare (IGJ). This rare background gives her a unique perspective and understanding of the life sciences sector. In her
practice, Hanneke advises life sciences and healthcare clients and litigates
on a wide range of issues. Areas of expertise cover marketing authorisations, reimbursement, compliance, pharmacovigilance, advertising issues, product
liability, issues on the interface of IP and regulatory, and —finally —
regulatory assistance in transactions. For the use of M&A or for the comfort of investors, Hanneke is able to provide tailor-made Transaction Regulatory Compliances prognosis reports. Hanneke is a university lecturer in Leiden and she publishes frequently on regulatory life sciences issues, such
as new European legislation and the impact of recent judgments in the sector.

Heather Beach is the founder and Managing Director of Healthy Work Company. She has been running businesses in the health and safety community for over 20 years.
Having started in information services running the first available health and safety service from HSE on CD-ROM at SilverPlatter – she moved to Barbour and then to Safety & Health Expo, SHP, and IOSH conference.
Heather is a specialist in organisational cultural change and delivers training to large global organisations in better wellbeing, empowering thriving at work. 
Heather is the founder of Women in Health and Safety and the Barbour webinar series which attracts over 3000 attendees a month.

Heidi is a sought after inspirational and informative speaker. Sharing her own experiences related to drug deliver and patient centricity, as well as details gleaned from her extensive global network. She speaks on a variety of topics but HOPE is the treat that binds her story together .

Lear how to increase alignment between patients and life science companies from the most important stakeholder - the patient!

A 2 time cancer survivor, Heidi uses her experiences to help others. She has held various Board positions with the the ACS, DOD and other cancer research and support organizations worldwide.

Dr. Heiko Schmidt is a Senior Manager at Accenture Strategy based in Munich, Germany. He has over 15 years professional experience in Pharma & Life Sciences Industry. Heiko supports clients in the areas of growth strategies and commercial excellence.

Houri Simonian, Ph.D has held the position of Director of Chemistry for SGS Mississauga for the past 5 years. She has more than 20 years of experience in the pharmaceutical industry, including R&D and drug development.

Ian Cooper took over as CEO of Famar in March 2020, following the acquisition of Famar by the investment funds York Capital Management and Elements Capital Management, leading Famar’s recovery free of any external long term debt. Covid19 has provided Ian and the Famar team with an additional challenge to keep the manufacturing sites fully operational in Spain, Italy and Greece and to keep the Pharma 3PL business in Greece distributing essential medicines. Ian joined Famar in 2012 and has covered various Regional Operations roles, and before his last promotion Ian was Senior Vice President of Commercial Operations and Supply Chain. A Chemical Engineer, Ian has previous experience in the Hygiene products and Food FMCG industry sectors, covering roles in R&D, Plant Management, and Multi-site Technical and Operations leadership. A British citizen, Ian has lived and worked in France, Germany, Italy and Spain, and is currently based in Madrid.

The world is ever-changing and never more so than during and post COVID. How you and your staff or colleagues cope, especially in these times of change, is key to the ongoing success of your business and wellbeing of each individual. Ian Helps teams find peace in chaos, reducing stress levels, and using brain training to help individuals and teams thrive at work. Ian received his certificate in mindfulness and meditation from The School of Positive Transformation.

Dr. Marcu has over 15 years of experience in cannabis research, regulations, and operations.

Jean-Marc Gilson graduated with a degree in Chemical Engineering from the University of Liège (Belgium) and holds an Executive MBA degree from the IMD in Lausanne (Switzerland). Before joining the Roquette Group, he was Vice-President and Chief Operating Officer at Nusil Technology in California. Previously, he was Executive Vice President at Dow Corning, where he spent 21 years in Belgium, Japan and the United States.Jean-Marc Gilson’s main responsibility is to further accelerate the global growth of Roquette in plant-based ingredients for Food, Nutrition and Pharma markets.

Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over $10M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired. At his time at PCT as their COO he supported over 20 clinical trials in the Cell and Gene Therapy field. These trials ranged from Phase I to Phase III pivotal trials.
Former Chief Operating Officer of Progenitor Cell TherapyProcessed over 25 clinical trials for respective therapy customersResponsible for tech transferring Kite’s T-Cell therapy out of the NIH, Novartis’ cell therapy out of U-Penn and Adaptimmume’s cell therapy out of U PennCell processing / manufacturing experience that spans Phase I, II, & III therapies.

Jim Miller advises bio/pharm companies and CDMOs on manufacturing strategy. He is the founder and former president of PharmSource, the pharmaceutical outsourcing industry’s premier collection of market intelligence about contract manufacturing, which is now part of GlobalData. Jim has consulted to many of the top bio/pharmaceutical companies and contract research and manufacturing organizations. He previously served as a consultant in corporate strategy with the Boston Consulting Group and as an executive with several healthcare information companies. He holds an M.B.A. degree from the Stanford University Graduate School of Business.

John Davidson is the Head of Lonza’s largest Capsules & Health Ingredients site in the United States. Trained as an engineer and with unique experience in operations, quality, supply chain and customer service, he has lead the site through a period of unprecedented growth in recent years. John calls upon over 20 years of multi-national experience in the biopharmaceutical and consumer health industries to provide insight for the future of manufacturing in the United States.

Julien Meissonnier serves as Chief Scientific Officer for Catalent Pharma Solutions. Mr. Meissonnier has over 16 years of Global experience in pharmaceutical development. At Catalent, he leads the Global R&D organization providing technical and scientific leadership for the development of delivery systems for poorly soluble and permeable drugs that lead to approvable regulatory dossiers. His responsibilities include early stage screening activities, developing products, scale-up and technology transfer, directing clinical supplies and supporting product launches. Additionally, is a Board Member of Catalent Applied Drug Delivery Institute and served as Board Director of Alsace BioValley innovation cluster. He received his Engineer Degree in Physico-Chemistry from the ENSI in Caen, France.

Dr. Karl Abele has specialized in use and
development of hyphenated MS equipment since 1986 at the Ruhr University in Germany, where he obtained a Ph.D. in chemistry in 1990. He moved to Switzerland in 1990, where worked as MS application specialist for three GC/LC/MS manufacturers. In 2010 he joined Solvias, a Basle based contract
research organization serving pharmaceutical manufacturers worldwide. He is currently leading a group of 15 scientists, performing identification and quantification of impurities in drug products at ultra-trace level, as well as E&L studies. His team is using state-of-art equipment (HRAM-LC/MSMS e.g. ThermoFisher Q-Exactive Systems) in a GMP regulated environment. Dr. Karl Abele and his team have been involved in analytical evaluation of nitrosamines from the start in June 2018 and have continuously improved their methodology and software solutions applied.

Katherine Dutmer is an independent legal counsel with over 20 years experience in Life Science Industry with a focus on commercial contracting, intellectual property, governance/regulatory and M&A. Katherine supports clients in healthcare, agri, biotech, food and feed industry for which she acts as company lawyer on an interim basis, fills gaps in legal team’s capacity to deal with adhoc legal matters, joins or leads (legal) projects. Katherine is considered business savvy and has access to an extensive international network. Over the last 10 years Katherine specialized in trade secret protection (companies’ developed knowledge) as tangible asset and missing link in the valuation of companies. Prior to this, Katherine was Global Legal & IP Manager at Enza Zaden and trained attorney with Baker & McKenzie and Hogan Lovells. Katherine holds a law degree from Leiden University and is a frequent speaker at international conferences and Nijenrode Business University

https://www.linkedin.com/in/katherine-dutmer/

Kathleen Lava successfully completed her Ph.D. in Chemistry at the University of Leuven (Belgium) in 2012. Afterwards she performed postdoctoral research in the team of Prof. Richard Hoogenboom at Ghent University. In 2016, she started at Nelson Labs Europe as a Study Director for Extractables and Leachables. She is part of the team specialized in Large Volume Parenterals, Ophthalmics and Disposables, with focus on ophthalmic drug products.

Kelsey ACHENBACH joined Roquette as Head of Marketing for Pharmaceuticals beginning of 2017. She has a very diverse background in specialty chemicals and polymers, with a particular focus on healthcare and pharmaceuticals. Over her career, she has transitioned from operations management to commercial management, with a deep expertise in successful project management, strategic planning and implementation, as well as commercial sales and new business development. Thanks to a diversified career, Kelsey has an extensive global management experience.Ms. ACHENBACH holds an MBA from Columbia Business School and London Business School, and she also sits on the DCAT Advisory Council.

Kevin has over 30 years’ experience working in the healthcare sector, principally with pharmaceutical, biotechnology and business consultancy companies. He has been involved in the successful divestment and acquisition of many businesses, acting as advisor to major pharmaceutical and biotechnology companies. During his career Kevin has held senior positions in pharmaceutical research, alliance management, business development and transactions. Prior to Results Healthcare, he worked at Hoechst (Sanofi), Quintiles, Roche Pharmaceuticals, Inpharmatica and
PharmaVentures. Some of Kevin's latest transactions include: GSK’s divestment
of its Mississauga, Ontario manufacturing facility to Bora Pharmaceuticals, Bridgepoint's acquisition of PharmaZell, Hospira, a Pfizer company, on the divestment of its UK compounding business to Baxter, Sanofi's divestment of the Holmes Chapel manufacturing site to Recipharm, Sanofi's divestment of the global rights to LEUKINE® and associated manufacturing assets to Partner Therapeutics.

Kieran is a highly effective senior leader with over 30 years of working experience with pharma excipients and food ingredients. He is a Chemical Engineer from the Cork Institute of Technology in Cork Ireland and spent close to 28 years with FMC working in manufacturing, supply chain and quality roles. After the acquisition of FMC by DuPont in 2018, he became an integral part of the 'Quality' leadership team at Dupont Nutrition & Biosciences.

In his current role, he drives impactful and strategic initiatives at Pharma Solutions business of DuPont Nutrition & Biosciences by delivering value to create innovative pharmaceutical formulation solutions utilizing the safest, most reliable raw materials for a high-quality product for customers. Kieran has rich cross-regional working experience working at several locations and positions in Europe and the US, primarily in manufacturing and supply chain roles.

Ms Kiran Mazumdar-Shaw is a pioneering biotech entrepreneur, a healthcare visionary, a global influencer and a passionate philanthropist. She is a pioneer of India’s biotech industry and founder of Biocon. She is the proud recipient of two of India's highest civilian honours, the Padma Shri and Padma Bhushan. She has recently been named as the winner of EY World Entrepreneur of the Year™ 2020 Award, which is a testimony to her entrepreneurial journey of over four decades.

Koichi Yamada, at Fujifilm Toyama, is the global head of Avigan project. Avigan, favipiravir, is an antiviral drug approved as anti-influenza drug in Japan, and has broad spectrum against RNA viruses.Since the COVID-19 Pandemic occurred, various parties are doing efforts to demonstrate the efficacy of facipiravir against COVID-19 internationally. Recently, Dr Reddy’s and Global Response Aid formulate an agreement with FUJIFILM Toyama to accelerate the clinical development and enlarge the supply capacity. He played a key role in shaping this alliance.

A clinical doctor by background, Dr. Palanivel completed his Master's in International Healthcare Management to explore larger avenues of creating value for patients in healthcare on a global level. He perceives digital health as a medium to champion the cause of
patient centricity and make personalized healthcare an absolute reality. He embraces PatchAi's mission of using state-of-the-art digital technologies to aid the go-to-market time for innovative therapies through the digitilization of clinial studies whilst engaging patients at every step of their care journey.

Kyoung Lim is a senior director of Supply Chain Management at Samsung Biologics, overseeing supply chain activities related to strategic sourcing & procurement, supplier relation management, material planning and logistics. Prior to joining Samsung Biologics, Kyoung held various positions in Procurement, Supply Chain, Project Management, and Product Portfolio , Management at Lonza.

Lauren is an experienced Health and Wellbeing Consultant and trainer, with a track-record of working with leading companies to design, implement and communicate wellbeing strategies that create meaningful change.
Her background as Editor (health, safety and wellbeing) and Head of Training (mental health and wellbeing) has given her a deep understanding of the challenges companies have relating to wellbeing programmes. 
Lauren delivers face to face training across the UK in Mental Health First Aid, courses from the shop floor to the board room and train the trainer programmes - as well as webinars globally. 
Lauren passionately believes that a focus on wellbeing has a genuine impact on the lives of employees and contributes greatly to business success.

Lee Taylor is a principal consultant in Korea Health Industry Development Institute (KHIDI), which is a government-affiliated institute. He has a wide range of experiences and distinctive profile in the healthcare industry such as bio pharmaceuticals, cosmetic, CMO, etc. He’s major business field is business development, Marketing and license &patent. He has worked as Menarini General Manger for 7 years, Daiichisankyo Sales Force Director for 5 years, Novartis National Sales Manager for 3 years and GSK Area Business Manager for 4 years.

Managing Director of Galentis srl. Past President and currently Board member Of CPA.
He frequently represents CPA in task force, technical meetings and conferences.

Lucia Aleotti graduated with honors in Economics with a thesis on Drug Patent Law.

In June 2001, Lucia Aleotti joined the Board of Directors of A. Menarini srl, parent company of the Menarini Group, together with her brother Alberto Giovanni.

Following the retirement of her father for health reasons, in September 2011 Lucia Aleotti became Vice President and led the company with her brother. In February 2013 she was appointed President serving until June 2018 when Dr. Eric Cornut was nominated.

In 2007 the Regional Council of Tuscany awarded Lucia Aleotti the Silver Banner (Gonfalone d’Argento) in recognition of talented young entrepreneurs.

Currently she is a member of Farmindustria’s Committee of the Presidency and of its Council of Association. She also serves on Confindustria’s Executive Council and General Council.

Lucia Aleotti helded other various positions in pharmaceutical industry associations:

- In Farmindustria (the Italian association of pharmaceutical industries) Lucia Aleotti was Vice President with responsibility for sector’s industrial plan, Member of the Committee of the Presidency and President of the Research Commission;
- In Confindustria, Lucia Aleotti was Member of the Technical Committee for Economic Development, Member of tha European Technical Committee and Member of the Board of Management;
- In EFPIA (the European Federation of Pharmaceutical Industries and Associations) Lucia Aleotti was Member of the Board, Heads of Europe, Member of EU Enlargement Team and Member of the Economic and Social Policy Committee;
- In IFPMA (the International Federation of Pharmaceutical Manufacturers & Associations) she was a Council Member;
- Lucia Aleotti was a member also of the World Biopharmaceutical CEO Roundtable (BCR)

Dr. Boltri is a pharmaceutical chemist by training and completed his degree at the University of Turin, With 30 years of experience in the Pharmaceutical Industry, Dr Boltri has held leading positions as Department Head and Director. 
In the current role, he is responsible for identifying new and innovative technologies as well as valuable opportunities for product development and co-development.

Ly has over 20 years of experience in the healthcare and pharmaceutical industry and has extensive experience in market research and analysis. Ly is currently the Director of Commercial Strategy at Informa Pharma Intelligence where she leads the strategy for partnership
opportunities with clients on thought leadership and custom projects. Ly
first joined Informa in 2010 as an analyst at Datamonitor Healthcare, a service within Informa that specializes in in-depth market assessment and drug forecasts. More recently, she led a global analyst and market access team as the Vice President of Disease Analysis and Strategy, and she oversaw the content strategy and thought leadership program as Head of Content Strategy and Thought Leadership. Ly has a PhD in Pharmacology from the University of New South Wales, Sydney, Australia and conducted R&D research at Johnson and Johnson prior to joining Informa.

Dr. Mahesh Bhalgat holds a Ph.D. in Medicinal Chemistry from the University of Utah, the USA, and a bachelor’s degree in Pharmacy from the University of Mumbai. He has over 25 years of experience in both biotechnology and biologics. Dr. Mahesh has worked in different facets of R&D which include analytical development, technology transfer, regulatory sciences and quality. During his career, he has been associated with companies such as Celera Genomics, Molecular Probes, Monsanto and Amgen.  Prior to joining Syngene, he was the Chief Operating Officer at Shantha Biotechnics, a Sanofi company, where his responsibilities included operations and long-term strategic planning and development. As Chief Operating Officer and a member of the Executive Committee at Syngene, Dr. Mahesh Bhalgat is responsible for operational efficiency, safety, quality and compliance.

Marieke van Dalen, Aspen Oss B.V., The Netherlands Marieke van Dalen is the global regulatory specialist in the regulatory group dedicated to APIs, with over 30 years of experience in the regulatory field. She is a board member of APIC, the European API Industry organization, and she participates in a number of task forces. She frequently represents APIC in meetings and conferences organized by EMA, EDQM, CPhI etc.

Mark Tunkel is Director of Business Development for Insight Innovation Center Chicago at Nemera. With more than 20 years of global business development experience and a deep understanding of the marketplace challenges and trends impacting the pharmaceutical industry, Mr Tunkel has advised many of the world’s leading companies on their device and product development strategies with an emphasis on driving realization and
the most favorable business outcomes.

Mike Whelan is an Immunologist working as a Project Leader for CEPI (Coalition for Epidemic Preparedness Innovations). His portfolio includes vaccines for Rift Valley Fever, platform technologies and, more recently, COVID-19. CEPI funds the development of vaccines for neglected pathogens with epidemic potential from preclinical development right through to licensure, partnering with both academic and commerical entities. He joined CEPI in December 2017. Mike has over 20 years of industrial biotechnology and 8 years of academic experience. He had his own consultancy company and was formerly R&D director at iQur, (working on VLP based universal influenza vaccines) and the Head of Research at Onyvax Ltd (whole cell vaccines for prostate cancer). Mike is an Honorary Lecturer at the Royal Veterinary College, a fellow of the Royal Society of Biology and has some 40 published papers and 4 patents.

CEO of Bone Therapeutics and visiting Professor at the Lisbon University in Portugal. Member of Alliance for Regenerative Medicine (ARM) Board of Directors. Previously CEO of Zelluna Immunotherapy from 2017 to end of 2019. Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy (ISCT) between 2016 and 2020. From 2006 to 2010 was VP of Global Medical Affairs at UCB. In 2004, joined Nabi Pharmaceuticals as the VP of Clinical, Medical and Regulatory Affairs in Europe. After several clinical, academic and regulatory positions in the public sector in Portugal and at the EMA, spent six years with Bristol-Myers Squibb in various positions including Country Medical Director, Executive Director of Infectious Diseases, Immunology and Dermatology and VP of International Medical Organization in Portugal and Belgium. Holds an M.D. from the Faculty of Medicine of the University of Lisbon, Portugal, and a Ph.D. in Immunology from the University of Birmingham, UK, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies (HEP). He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.

Nicholas Brooke is Founder of The Synergist, which is a collaboration incubator acting as a backbone, providing vision, strategy, stakeholder alignment and execution on multiple international, multi-stakeholder programs aiming to solve significant societal issues. It includes Patient Focused Medicines Development (PFMD), an international collaborative platform dedicated to stimulating innovation in improvement of global health through systematic engagement with patients.

Nigel Langley, Global Technology Director, BASF Pharma Solutions provides technical support to the pharmaceutical industry and helps solve drug formulation challenges. He has held various senior technical and marketing positions during his 11 years at BASF. Nigel has also worked in Japan and England with Croda International prior to joining BASF. He gained his Chemistry (Hons) degree and PhD (Liquid Crystals) from the University of Hull (UK) and an MBA from Leeds University (UK). He also took a 2 -year Postdoctoral research position at Leeds University (UK) in natural product synthesis. He has over 100 scientific publications and has co-edited 2 books. Nigel is an adjunct professor at the University of Mississippi and a Fellow of the Royal Society of Chemistry (UK). In 2018 he was awarded the Industry Research Achievement Award in Excipient Technology by the IPEC Foundation. He has been a member of the Executive Committee at IPEC Americas since 2010 and is currently Chair Elect. He is also helping to lead the Novel Excipients initiative for IPEC Americas in collaboration with the IQ Pharma Consortium. Nigel is on the Medicine Maker’s Power List for 2020 for small molecules.

Graduated in industrial chemistry in Milan, he started working in Profarmaco in 1971, dealing with engineering and
maintenance, at the factory in Paullo. In the ten years spent in Paullo, he
had the opportunity to learn the various aspects of a company producing
pharmaceutical active ingredients: logistics, scale up of new products from
RD to pilot to commercial production, production planning, introduction of
industrial costs from scratch, purchasing, management control, interaction with the commercial department. In 1982 he became General Manager and CEO and moved to the Milan office, where he also managed sales and administration. In 1989 Profarmaco is sold to the Swedish Nobel Industries, which leaves him in
charge of the company (Profarmaco Nobel) and also entrusts him with the
management of a second company in Italy. In 1991 the Akzo Nobel merger took
place and in 1994 Profarmaco was sold to Cambrex; in Cambrex he continues to
manage the Italian company and is also put in charge of the generics Business
Unit, for the whole group, becoming head of four production units in Europe,
and a member of the group's Executive Committee. In 2008 he became President of Cambrex Profarmaco Milano.

Parviz received both his BTech and PhD in Chemical Engineering from the University of Bradford, UK. As a chemical engineer, Parviz combines 37 years of academic and industry experience in bioprocessing with the focus on biopharmaceutical and biologic process development.

As Executive Director for JIB, Parviz leads all of the Institute’s activities including designing and delivering education and training, budgeting and financing, research and development, recruitment, program development, and fundraising for research and future growth.

At the core of Parviz’s philosophy and vision for education is the development and implementation of industry-facing programs to address the growing need for a skilled workforce in biomanufacturing.

Patrick Branch is a Partner in L.E.K.’s Tokyo office and a member of the firm’s Life Sciences practice. He works with businesses and investors in the biopharmaceutical, medical device and broader healthcare sectors. He advises clients on a range of topics, including commercial strategy, corporate and business unit strategy, pricing and market access and M&A.
Patrick joined L.E.K. in 2007 and has worked in the firm’s Tokyo, Singapore, New York and Boston offices. He previously held commercial strategy and business development roles at the Japanese subsidiary of AstraZeneca and the Singapore subsidiary of Biogen. He received a Master of Business Administration from INSEAD and a Master of Public Health from Columbia University. He also holds degrees from the University of London and the University of Nottingham.

Pavel Kubu MD is the expert in the fields of medical informatics and adictology. In 2001, graduated in general medicine with a focus on diseases prevention at Charles University in Prague, 3rd Medical
Faculty. Since 2005 to 2015 worked for Intel Corporation as the Business Development Manager leading projects for Healthcare and Education in Central
and Eastern Europe. In 2006 apointed as chairman of the Ethical Commission of
the National Monitoring Center for Drugs and Drug abuse of the Czech republic goverment. Serves since 2007 as the board member of the Czech National Forum for eHealth where he is focused on research and development of new treatment and preventive methods utilizing eHealth tools for personalised care. 2015 became co-founder of International Cannabis and Cannabinoids Institute which
is focused on clinical research and development of medical cannabis treatment methods, evaluation on quality of cannabis products, CME and development of new care models modulating endocannabinoid system. Americans for Safe Access NGO has elected Dr.Kubu as the board member of this biggest cannabis patient’s organization globaly in 2019. Becoming also the first non-US citizen member of the ASA board.

Peter is the President of xCell Strategic Consulting, a consulting firm to the Pharmaceutical Industry.  xCell provides consulting services in the areas of Drug Development, Outsourcing, and Supply Chain.  In addition, xCell Provides advice and support for M&A in the Pharmaceutical Services Industry.  Prior to founding xCell, Peter served as Division President of Qualitest, Endo Pharmaceutical’s Generic Drug Division. He also served as the President of North America Commercial Operations and CEO at Patheon Pharmaceuticals.  Patheon is a leading Contract Manufacturing and Contract Research Organization which at the time was Publicly Traded and had $700 million in revenues and 5000 employees.    Prior to joining Patheon, Peter spent 14 years with Wyeth Pharmaceuticals.  While at Wyeth, he oversaw a significant portion of the Manufacturing and Supply Chain organization including Consumer Products such as Advil and Centrum Vitamins, Branded Drug Products and Vaccines such as Prevnar.  He also oversaw Global Engineering and expansion programs to support drug manufacturing and Research and Development. .  Peter also spent 14 years at SmithKline Beecham (now GlaxoSmithKline) before joining Wyeth.  His assignments included significant international project work in Europe and the Far East and operations experience with injectable product manufacturing.

Peter is a member of the Global Pharmaceutical Manufacturing Leadership Forum of the ISPE and is a frequent speaker at Industry events.  He serves as the Chairman of the Board of Trustees of the Pharma, Biopharma Outsourcing Association (PBOA); a non-profit trade association that represents the needs and interests of Pharmaceutical Contract Development & Manufacturing Organizations (CDMOs).  Peter previously served on the Board of IPS – a Global Healthcare Engineering Company,  the Board of Frontida Laboratories and the Board of CASA Youth Services – a non profit organization serving the needs of Children in the Foster Care environment.  He has a BS in Mechanical Engineering from Villanova University and an MBA from Philadelphia University.  Peter and his wife Lynn reside in Valley Forge, Pennsylvania.

Peter Shapiro, PhD, is Senior Director of the Drugs and Business Fundamentals and also serves as the Editor-in-Chief of PharmSource. Peter is a thought leader in Contract Pharmaceutical manufacturing. Prior to joining GlobalData, Peter was at Target Health, a Contract Research Organization (CRO). Peter also worked in small molecule drug development for Abbvie and on in vitro diagnostics at a diagnostic startup. Peter holds a PhD in Molecular and Cellular Biology from the Sackler Institute of New York University and is located in GlobalData’s office in New York City.

Sai Shankar is the Vice President, Global Digital Healthcare Systems at Aptar Pharma. Sai has 18 years of product development and business strategy experience in the pharmaceutical industry. He joined Aptar in April 2017, having had previous roles at Allergan and Sanofi, where he was Head of Packaging Development and also lead CMC teams. Sai has recently presented at international events, including Pharmapack in Paris, CPhi in Frankfurt, Innovative Drug Delivery Solutions Symposium in China and Nasal Drug Delivery in the UK.

Sarah Hardison is Head of Product, Regulatory at Clarivate Analytics. Prior to joining Clarivate, Sarah worked in Product and Portfolio Management in Life Sciences companies, helping to deliver to enable drug development and novel drug discovery. Sarah earned her PhD in Immunology at the University of Texas.

Education: - Ph.D. in Pharmacy, Tokyo University, 2010 Qualification: - Doctor of Pharmacy Experience: - 2018 – Current: Bachem Japan K.K., - 2009 – 2018: Meso Scale Diagnostics, LLC., Sato Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co. Ltd. - 1995 – 2009: Banyu Pharmaceutical Co., Ltd. Research Pharmacologist.

Dr. Sawsan A. S. Al Madhi has more than 18 years progressive leadership skills and experience in strategy, operations and
administration for the not-profit charitable sector. Currently working with one of the most reputable charities in the UAE as the Director General for Friends of Cancer Patients, Dr. Sawsan’s role is to supervise the continuing refinement and expansion of the organizational objectives which include:
providing high quality services, organizing fundraising activities,
developing ,planning and executing nationwide awareness programs and
campaigns through collaboration with a vast network of national and
international, governmental and private sector organizations.

Scott Watson is VP and Head of Commercial Operations at Benuvia Manufacturing. He also serves as Principal of The C=C Bond Group which provides strategic and tactical advisory consulting services to
pharmaceutical and biotechnology companies. Previously, Mr. Watson held sales and operational leadership positions at Eastman Chemical Company, Durect Corporation, DSM, and AMPAC Fine Chemicals. Since 2000, he has served as a Professor and Adjunct Professor at the University of Alabama at Birmingham.
Mr. Watson received an MBA from George Mason University and a BS in Chemistry from the US Naval Academy. He holds the Chartered Financial Analyst ® (CFA) designation.

Physician; Former Commissioner Food and Drug Administration (2017-2019); Former Senior Advisor – CMS

Sebastian Stolzenberg is a postdoctoral project leader at Free University of Berlin, holds a Physics Ph.D. from Cornell University, and is a former Fulbright Fellow. During his dissertation under Prof. Harel Weinstein in New York, he studied detailed molecular mechanisms of transmembrane proteins, whereas in Berlin under Prof. Frank Noé, he now
investigates with supercomputers at Oak Ridge National Laboratories molecular aspects of the adaptive immune system. He has recently developed a deep neural network (AI) software to predict immunogenicity of linear epitope and proteins.

Sharon Cunningham is co-founder of Shorla Pharma, an Irish specialty pharmaceutical company. A driven and compassionate company, Shorla Pharma have developed an innovative pipeline of oncology drugs focusing on women’s and children’s cancers. The company raised €7.5m in Series A funding in June 2020. Sharon was awarded the title of Ireland’s Best Young Entrepreneur 2019 and was included on a list of 50 people to look out for in 2020 by the Irish Times. She also won the prestigious Worldwide Association of MBA's Best Entrepreneurial Venture Award (Private Sector) 2020. In 2019 she led an international team to win the MIT-Harvard Medical School Healthcare Innovation Bootcamp Pitching Competition in Boston, US. Having graduated with an MBA from University College Dublin Smurfit School in 2015, Sharon went on to co-found Shorla Pharma with her former EirGen Pharma colleague, Orlaith Ryan. Sharon is also a PwC qualified Chartered Accountant and holds a BSc in Finance from University College Cork. She sits on the board of Irish Rule of Law International.

Dr. Shirley O’Dea co-founded Avectas in 2012 and is the company’s CSO, in addition to serving on the Board of Directors. She is charged with evaluating, overseeing and implementing both the internal and external scientific programs at Avectas. With a scientific career in cell biology extending over 25 years, prior to co-founding Avectas Shirley completed research fellowships at University of Edinburgh Medical School and also served as a Principal Investigator for several industry collaborations.

Sian Estdale is the Head of Scientific Affairs within Clinical Trials Testing Solutions at Covance where she has worked since 2002. Her expertise is in methodologies to support drug development of molecules, especially biologics from R & D to market in CMC and BioA and now patient care analysis. Previous to Covance, Sian was an academic, lecturing in Biomedical Sciences at Bradford and Sheffield Hallam Universities with 14 years research experience in diverse areas: recurrent miscarriage, ischemia-reperfusion and skin research. She has a PhD in organic chemistry.

Dr. Srividya Ramakrishnan heads Process Engineering (API) at Dr. Reddy’s Laboratories. She has a doctorate in Chemical Engineering from Princeton University, and worked at Unilever Research and Bristol-Myers Squibb in New Jersey prior to joining Dr. Reddy's in 2008. She is also an ASQ-certified Six Sigma Black Belt and has several patents and publications to her credit. She has actively participated in furthering Diversity & Inclusion initiatives at Dr. Reddy’s and has recently taken up an additional role as Chief Diversity Officer.

Stephanie is the Editor of Texere Publishing’s The Medicine Maker and The Small Molecule Manufacturer brands, which focus on showcasing the pharma industry’s success stories and biggest points of contention. Stephanie has been writing about the trends and technologies shaping the industry for over a decade and has been involved with The Medicine Maker since its initial launch. She has a degree in Creative and Professional Writing and specializes in conveying the stories behind the science.

Steve Brooks currently serves as an Advisor to the Antimicrobial Resistance (AMR) Industry Alliance, and chairs the Manufacturing Work Group of the Alliance. Prior to this engagement, Steve gained almost 37 years of pharmaceutical industry experience in the UK and the US with Pfizer in roles of increasing complexity, scope and responsibility. Steve has mentored many colleagues, formally and informally, developed and implemented major corporate programs and is a recognized EHS leader in the pharmaceutical industry.

A Chartered Biologist and GSK Senior Fellow with a Masters degree in Industrial Pharmacy and PhD in Pharmaceutics. Currently working in Pharmaceutical Development (PD), Terry has over 25 years experience in the pharmaceutical industry at GSK, spanning R&D and Commercial Supply. In addition to being a Team Leader within PD, Terry also leads a global group focused on age appropriate product development and is a member of a number of Paediatric focus groups within and external to GSK. Terry is passionate about age appropriate drug development and continues to actively research and collaborate with academia and other industry partners.

Dr. Thomas VanCott joined Paragon Gene Therapy following 14 years as the President and CEO of Advanced Bioscience Laboratories, Inc. (ABL), a contract manufacturing and laboratory research services company. Before joining ABL, he held several positions at the Henry M. Jackson Foundation for the Advancement of Military Medicine. He also served as a U.S. Army Captain in the Medical Service Corps at Walter Reed Army Institute of Research. Dr. VanCott received his PhD in Physical Chemistry from the University of Virginia and a B.S. degree in Chemistry from Dickinson College.

Tim McLeroy is Executive Director of Marketing and Patient Services at Noble, an Aptar Pharma company, where he leads the development and execution of product and service launch initiatives, and directs Noble’s marketing strategies. Prior to Noble, Tim led the Nayzilam® launch for UCB’s U.S. Neurology Patient Value Unit and served as the stakeholder execution lead for UCB’s immunology business in the U.S., with work in biosimilar strategy.

Tom has worked at Hanway since 2018 leading a broad range of projects with medical and wellness (CBD) companies. He has particular interests in go-to-market strategies for companies looking to break into Europe as well as the intersection between technology and healthcare. Prior to Hanway Tom spent 8 years as a Management Consultant at Accenture and IQVIA, working with large pharma companies across Europe.

Victoria Morgan has been in the pharmaceutical industry for more than 25 years with extensive experience across primary and secondary care and the area of injection drug delivery products, such as primary packaging and combination products for vial, prefilled syringe systems, cartridges and devices.
Throughout her tenure at West, she has served in various functions across sales and marketing. Victoria spent more than 17 years in global sales roles followed by 3 years as Director of Segment Marketing, Biologics here at West, where she has responsibility for global biologics strategy development and implementation.

Yasemin is a Consultant in the European Thought Leadership team based in IQVIA’s London office. Her primary areas of focus are; trends in innovative launches, drug delivery and formulations as well as the oncology market with emphasis on commercial trends. She has presented and moderated panels on these subjects in a variety of conferences. Yasemin holds a Masters in Cancer Research and a Bachelor of Science degree in Biomedical Sciences both from Newcastle University. Prior to her role in Thought Leadership, Yasemin was part of the Real-World Insights – Global Oncology team where she worked on the co-ordination and set-up of reports focusing on various cancers.

Dr. Sharma has over 15 years of experience in applying and managing data science and machine learning approaches to solving complex problems in the healthcare space. Yugal was a scientist for the National Institutes of Health (NIH), focusing on developing early disease detection algorithms. Since NIH, Yugal helped found a technology startup, followed by a business consulting startup. More recently, he applied his background as a consultant working with commercial and federal agencies to help advance their data science strategies. He has published several scientific articles, as well co-authoring a book chapter on the mining of Electronic Health Records to detect disease signals.
He is currently the Sr. Director of Solutions for CAS Services which creates customized approaches for your unique scientific information challenges – from AI/ ML initiatives, to faster workflows, and novel approaches to unlock value out of scientific data. Yugal received his PhD in Biophysics from University of Cincinnati, where he graduated with honors.